Gastroenterological symptoms in COVID-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy

Background. The novel coronavirus infection COVID-19 can be manifested by damage to the organs of the gastrointestinal tract (GIT). Damage to the gastrointestinal tract by the SARS-CoV-2 virus leads to a violation of the microbial-tissue complex of the mucous membrane of the digestive tract. A commo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maria D. Ardatskaya, Ludmila I. Butorova, Marina A. Kalashnikova, Nelli R. Nugaeva, Yury V. Ovchinnikov, Olga S. Oynotkinova, Aleksandr I. Pavlov, Roman G. Plavnik, Elena V. Sayutina, Tatiana В. Topchiy, Svetlana N. Trunova
Formato:	article
Lenguaje:	RU
Publicado:	"Consilium Medicum" Publishing house 2021
Materias:	covid-19 gastrointestinal symptoms diarrhea microbiocenosis zacofalk ibs-like disorders Medicine R
Acceso en línea:	https://doaj.org/article/654e7feefea74ee0940e5d95ab676792
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:654e7feefea74ee0940e5d95ab676792
record_format	dspace
spelling	oai:doaj.org-article:654e7feefea74ee0940e5d95ab6767922021-12-01T12:22:36ZGastroenterological symptoms in COVID-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy0040-36602309-534210.26442/00403660.2021.08.201020https://doaj.org/article/654e7feefea74ee0940e5d95ab6767922021-08-01T00:00:00Zhttps://ter-arkhiv.ru/0040-3660/article/viewFile/79522/60144https://doaj.org/toc/0040-3660https://doaj.org/toc/2309-5342Background. The novel coronavirus infection COVID-19 can be manifested by damage to the organs of the gastrointestinal tract (GIT). Damage to the gastrointestinal tract by the SARS-CoV-2 virus leads to a violation of the microbial-tissue complex of the mucous membrane of the digestive tract. A common gastroenterological manifestation of COVID-19 is diarrhea. Aim. Study of the clinical features of gastroenterological disorders and the possibility of optimizing the treatment of diarrheal syndrome in patients with COVID-19 with a mild form of viral infection. Materials and methods. The observation group consisted of 230 patients with mild COVID-19: K-group (n=115) with respiratory symptoms, I group (n=115) with gastrointestinal manifestations in combination and without signs of respiratory damage. In order to compare the effectiveness of treatment of diarrheal syndrome, patients of group I are randomized into 2 subgroups: Ia (n=58) prebiotic treatment (Zacofalk) and Ib (n=57) enterosorbents. Results. The development of gastrointestinal symptoms with SARS-CoV-2 infection is significantly more often noted in comorbid patients (67%). Gastrointestinal symptoms were dominated by diarrhea (93.9%) and flatulence (76.5%), in 1/3 of patients they were the first manifestos of infection. It was established that in 98.4% of patients of group I (against 42.6% of the K-group) signs of infectious intoxication were detected. In patients with gastrointestinal lesions, an elongation of the febrile period by 91.5 days was noted, a later (6 days) verification of the viral etiology of the disease. It was found that in patients of group I, the regression of clinical symptoms, the duration of viral disease, the dynamics of antibody formation, the prognosis for the development of IBS-like disorders in the post-infectious period depended on the treatment. In patients taking (Zacofalk), these indicators were significantly better. Conclusion. In mild cases, to reduce the severity of viral intestinal damage, for effective relief of intestinal symptoms, to reduce the risk of IBS-like symptoms, it is advisable to prescribe (Zacofalk) in an initial dose of 3 tablets per day.Maria D. ArdatskayaLudmila I. ButorovaMarina A. KalashnikovaNelli R. NugaevaYury V. OvchinnikovOlga S. OynotkinovaAleksandr I. PavlovRoman G. PlavnikElena V. SayutinaTatiana В. TopchiySvetlana N. Trunova"Consilium Medicum" Publishing housearticlecovid-19gastrointestinal symptomsdiarrheamicrobiocenosiszacofalkibs-like disordersMedicineRRUТерапевтический архив, Vol 93, Iss 8, Pp 923-931 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	covid-19 gastrointestinal symptoms diarrhea microbiocenosis zacofalk ibs-like disorders Medicine R
spellingShingle	covid-19 gastrointestinal symptoms diarrhea microbiocenosis zacofalk ibs-like disorders Medicine R Maria D. Ardatskaya Ludmila I. Butorova Marina A. Kalashnikova Nelli R. Nugaeva Yury V. Ovchinnikov Olga S. Oynotkinova Aleksandr I. Pavlov Roman G. Plavnik Elena V. Sayutina Tatiana В. Topchiy Svetlana N. Trunova Gastroenterological symptoms in COVID-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy
description	Background. The novel coronavirus infection COVID-19 can be manifested by damage to the organs of the gastrointestinal tract (GIT). Damage to the gastrointestinal tract by the SARS-CoV-2 virus leads to a violation of the microbial-tissue complex of the mucous membrane of the digestive tract. A common gastroenterological manifestation of COVID-19 is diarrhea. Aim. Study of the clinical features of gastroenterological disorders and the possibility of optimizing the treatment of diarrheal syndrome in patients with COVID-19 with a mild form of viral infection. Materials and methods. The observation group consisted of 230 patients with mild COVID-19: K-group (n=115) with respiratory symptoms, I group (n=115) with gastrointestinal manifestations in combination and without signs of respiratory damage. In order to compare the effectiveness of treatment of diarrheal syndrome, patients of group I are randomized into 2 subgroups: Ia (n=58) prebiotic treatment (Zacofalk) and Ib (n=57) enterosorbents. Results. The development of gastrointestinal symptoms with SARS-CoV-2 infection is significantly more often noted in comorbid patients (67%). Gastrointestinal symptoms were dominated by diarrhea (93.9%) and flatulence (76.5%), in 1/3 of patients they were the first manifestos of infection. It was established that in 98.4% of patients of group I (against 42.6% of the K-group) signs of infectious intoxication were detected. In patients with gastrointestinal lesions, an elongation of the febrile period by 91.5 days was noted, a later (6 days) verification of the viral etiology of the disease. It was found that in patients of group I, the regression of clinical symptoms, the duration of viral disease, the dynamics of antibody formation, the prognosis for the development of IBS-like disorders in the post-infectious period depended on the treatment. In patients taking (Zacofalk), these indicators were significantly better. Conclusion. In mild cases, to reduce the severity of viral intestinal damage, for effective relief of intestinal symptoms, to reduce the risk of IBS-like symptoms, it is advisable to prescribe (Zacofalk) in an initial dose of 3 tablets per day.
format	article
author	Maria D. Ardatskaya Ludmila I. Butorova Marina A. Kalashnikova Nelli R. Nugaeva Yury V. Ovchinnikov Olga S. Oynotkinova Aleksandr I. Pavlov Roman G. Plavnik Elena V. Sayutina Tatiana В. Topchiy Svetlana N. Trunova
author_facet	Maria D. Ardatskaya Ludmila I. Butorova Marina A. Kalashnikova Nelli R. Nugaeva Yury V. Ovchinnikov Olga S. Oynotkinova Aleksandr I. Pavlov Roman G. Plavnik Elena V. Sayutina Tatiana В. Topchiy Svetlana N. Trunova
author_sort	Maria D. Ardatskaya
title	Gastroenterological symptoms in COVID-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy
title_short	Gastroenterological symptoms in COVID-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy
title_full	Gastroenterological symptoms in COVID-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy
title_fullStr	Gastroenterological symptoms in COVID-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy
title_full_unstemmed	Gastroenterological symptoms in COVID-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy
title_sort	gastroenterological symptoms in covid-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy
publisher	"Consilium Medicum" Publishing house
publishDate	2021
url	https://doaj.org/article/654e7feefea74ee0940e5d95ab676792
work_keys_str_mv	AT mariadardatskaya gastroenterologicalsymptomsincovid19patientswithmildseverityofthediseaseopportunitiestooptimizeantidiarrhealtherapy AT ludmilaibutorova gastroenterologicalsymptomsincovid19patientswithmildseverityofthediseaseopportunitiestooptimizeantidiarrhealtherapy AT marinaakalashnikova gastroenterologicalsymptomsincovid19patientswithmildseverityofthediseaseopportunitiestooptimizeantidiarrhealtherapy AT nellirnugaeva gastroenterologicalsymptomsincovid19patientswithmildseverityofthediseaseopportunitiestooptimizeantidiarrhealtherapy AT yuryvovchinnikov gastroenterologicalsymptomsincovid19patientswithmildseverityofthediseaseopportunitiestooptimizeantidiarrhealtherapy AT olgasoynotkinova gastroenterologicalsymptomsincovid19patientswithmildseverityofthediseaseopportunitiestooptimizeantidiarrhealtherapy AT aleksandripavlov gastroenterologicalsymptomsincovid19patientswithmildseverityofthediseaseopportunitiestooptimizeantidiarrhealtherapy AT romangplavnik gastroenterologicalsymptomsincovid19patientswithmildseverityofthediseaseopportunitiestooptimizeantidiarrhealtherapy AT elenavsayutina gastroenterologicalsymptomsincovid19patientswithmildseverityofthediseaseopportunitiestooptimizeantidiarrhealtherapy AT tatianavtopchiy gastroenterologicalsymptomsincovid19patientswithmildseverityofthediseaseopportunitiestooptimizeantidiarrhealtherapy AT svetlanantrunova gastroenterologicalsymptomsincovid19patientswithmildseverityofthediseaseopportunitiestooptimizeantidiarrhealtherapy
_version_	1718405177274269696

Gastroenterological symptoms in COVID-19 patients with mild severity of the disease: opportunities to optimize antidiarrheal therapy

Ejemplares similares